Salbutamol 10mg/tab 100 Tabletten by Dragon-Pharma

Usage

1. Calculate your β2 target dose: based on bodyweight and prior stimulant tolerance — a common starting reference is 0.1–0.15 mg/kg/day, consistent with dose ranges evaluated in clinical β2-agonist research.
2. Split tablets if needed: the 10 mg tablet can be physically halved to yield a 5 mg introductory dose, minimising peak plasma concentration and smoothing the onset of cAMP elevation during Day 1–5.
3. Time the first daily dose in the morning: β2-adrenoceptor density and Gs-protein coupling efficiency are highest in the early circadian window when endogenous catecholamines are elevated — co-administration amplifies cAMP production.
4. Schedule the second dose (if applicable) before 3 PM: salbutamol's CNS stimulant component, mediated partly via peripheral β2-receptor-driven adrenaline-like effects, can impair sleep onset if taken in the evening.
5. Monitor resting heart rate daily before dose escalation: an increase of more than 15 bpm above baseline suggests significant β1 receptor cross-activation and is a practical signal to hold dose, not increase it.
6. Enforce the two-week off-cycle without exception: skipping the receptor recovery window prevents β2-receptor re-expression and renders subsequent cycles ineffective, as GRK-phosphorylated internalised receptors require time for lysosomal recycling and resynthesis.

Warnings

Frequently asked questions

How does a β2 agonist like salbutamol act directly on fat cells?

Salbutamol binds to β2-adrenoceptors on the surface of adipocytes, triggering a Gs protein that activates adenylyl cyclase and converts ATP to cyclic AMP. The resulting cAMP surge activates protein kinase A, which phosphorylates hormone-sensitive lipase — the enzyme responsible for breaking stored triglycerides into free fatty acids and glycerol available for oxidation as fuel.

What physiological changes occur in the body when intracellular cAMP concentration rises after salbutamol intake?

Elevated cAMP activates protein kinase A across multiple tissue types simultaneously: in adipose tissue it accelerates lipolysis; in brown fat it upregulates UCP-1 expression, increasing thermogenic heat output; in skeletal muscle it can enhance glucose uptake and protein synthesis signalling. The net result is a shift in metabolic substrate utilisation toward fat oxidation and an increase in basal energy expenditure.

Why does the thermogenic and fat-burning effect of salbutamol diminish after two to three weeks of continuous use?

Sustained β2-receptor stimulation triggers desensitisation: G protein-coupled receptor kinases phosphorylate the occupied receptor, recruiting β-arrestin proteins that uncouple it from Gs signalling and promote receptor internalisation. The result is a net reduction in surface β2-receptor density, so the same dose produces less cAMP and proportionally less lipolytic and thermogenic output — which is why structured on/off cycling protocols are recommended.

Why is the 10 mg per tablet concentration of Dragon-Pharma Salbutamol the highest available in this format, and what advantage does that offer?

At 10 mg per tablet, Dragon-Pharma's Salbutamol delivers the highest unit dose in oral salbutamol tablet formats commonly used in body-composition protocols. This allows experienced users to achieve target daily doses — often in the 16–32 mg range during peak-cycle phases — with fewer tablets, and enables precise dose reduction simply by splitting one tablet, rather than managing multiple low-dose pills.

Can the 10 mg tablets be split or adjusted mid-protocol, and how does that support a β2 titration approach?

Yes — the compressed tablet format allows physical splitting for intermediate dose steps (e.g. 5 mg), which directly supports a β2-agonist titration approach where starting dose is kept low to assess cardiovascular and CNS tolerance before escalating. Beginning at 5–10 mg once or twice daily and titrating upward over 5–7 days minimises side-effect exposure during the period of highest receptor sensitivity at the start of a new cycle. (2) angle_used

Manufacturer

Dragon-Pharma's standing within the global performance-supplement marketplace was not built on marketing expenditure — it was built on a straightforward commitment made early in the company's history: that the API concentration stated on a product label must be the concentration measurably present in the finished dosage unit, verifiable by accredited analytical methods. For Salbutamol 10 mg, this commitment takes a specific form: each 100-tablet production batch is subjected to HPLC quantification in which per-tablet salbutamol content is measured against a certified reference standard before any unit is released for distribution. The company's GMP-compliant tableting infrastructure — established across Eastern European production facilities — incorporates raw-material API assay as a mandatory pre-blending gate, ensuring that only identity-confirmed salbutamol enters the compression process. This two-stage quality architecture (incoming API verification followed by finished-product HPLC) means that potency confidence is grounded in measurement data, not in formulation mathematics. Batch records for each production run are retained and available to support third-party audit, reflecting Dragon-Pharma's position that analytical transparency is the minimum standard consumers should expect from a pharmaceutical-grade supplier.